Year: 1998
Type: article
Abstract: OR many years, the Food and Drug Administration (FDA) regulated botanical dietary-supplement ingredients, in most circumstances, under the provisions for food additives of the Federal Food, Drug, and Cosmetic Act to ensure that they were safe and wholesome.Currently, dietary supplements (such as botanical products, vitamins and minerals, amino acids, and tissue extracts) are regulated under the Dietary Supplement Health and Education Act of 1994, which includes several provisions that apply only to dietary supplements and dietary ingredients of dietary supplements.Included in these provisions was the removal of the ingredients of dietary supplements from regulation as food additives and the requirement that the FDA bear the burden of proof that a marketed dietary supplement presents a serious or unreasonable risk under the conditions of use on the label or as commonly consumed.This requirement is in contrast to what is required for drugs, which must be shown to be safe and effective for a particular indication before they are approved for marketing.The case of a previously healthy patient who presented with a toxic serum digoxin level after the ingestion of botanical dietary supplements was reported to the FDA in 1997.We sought to determine the source of the patient's exposure to cardiac glycosides and to investigate the extent and duration of distribution of the suspect raw material and the products containing it.We also investigated a sec-
Source: New England Journal of Medicine
Language: English
Subfield: Complementary and alternative medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2328198341
